You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 9 No. 2, August 1963 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL ARTICLES
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on Web of Science (6)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Nylidrin Hydrochloride in Senile Arteriosclerosis

KEITH R. TREPTOW, MD; D. CRAIG AFFLECK, PhD; C. ALLEN ROEHL, PhD; WARNER M. SOELLING, MD

Arch Neurol. 1963;9(2):142-146.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

The scope of the problem of senile and arteriosclerotic brain syndromes is suggested by population and state hospital statistics. Between 1900 and 1950 the population of the United States doubled, while the number of persons aged 65 or over increased fivefold. Presently, 30% of the patients in state mental hospitals are over 65; of this group 41% are senile-arteriosclerotic. Nearly one third (27%) of all first admissions are over 65; of these over 80% are senile-arteriosclerotic.2

Because of the assumption that arteriosclerotic patients would benefit from improved cerebral circulation, vasodilators such as tolazoline hydrochloride (Priscoline) and 3-pyridinemethanol (Roniacol, the alcohol corresponding to nicotinic acid) have had extensive clinical use. That these agents actually do not increase cerebral blood flow has been established.12

Recent work with the vasodilating agent isoxsuprine hydrochloride (Vasodilan) demonstrated its effectiveness in increasing cerebral blood flow.5 A recent study of this drug 1 indicated . . . [Full Text PDF of this Article]


Footnotes

Submitted for publication April 20, 1963; accepted May 17, 1963.

Nebraska Psychiatric Institute, University of Nebraska College of Medicine (Dr. Treptow).

This study was supported in part by the National Institute of Mental Health, Public Health Service research grant MY-2784, and the US Vitamin & Pharmaceutical Corporation.

The US Vitamin & Pharmaceutical Corporation supplied the drug and the placebo.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1963 American Medical Association. All Rights Reserved.